Author: Flightpath Biosciences Inc.
-
Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease
BERKELEY, Calif. — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of…